Vectura Group develops therapies principally for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The company has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development. VEC has development collaborations and license agreements with several pharmaceutical companies, including Novartis, Sandoz, Baxter and GlaxoSmithKline. For more information, visit the company’s Web site: http://www.vectura.com
Let us hear your thoughts below: